Article

Sam Donaldson Discusses His Melanoma Diagnosis

In 1995, Sam Donaldson, ABC news veteran, found a lump that ultimately led to a diagnosis of melanoma.

In 1995, Sam Donaldson, ABC news veteran, found a lump that ultimately led to a diagnosis of melanoma. Donaldson consulted with a surgeon at the National Cancer Institute, who told him that with treatment, he would "live a long and healthy life."

While Donaldson was less optimistic about his survival, his oncologist assured him he would be fine and continued to update him on his prognosis. He joined a clinical trial where he underwent surgery, which showed only one lymph node to have cancer.

"One lesson I would like to pass on to people is that we want optimistic doctors," he says. "We want honest doctors ... but if you can be optimistic and give a patient who may think they have a death sentence some hope that's realistic, it does a wonderful bit of good."

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.